<DOC>
	<DOCNO>NCT00931125</DOCNO>
	<brief_summary>This study investigate hypothesis ranibizumab injection give eye safe , efficacious help treatment option apply surgical intervention proliferative diabetic retinal eye disorder .</brief_summary>
	<brief_title>Safety Efficacy Intravitreal Ranibizumab Preoperative Adjunct Treatment Before Vitrectomy Surgery Proliferative Diabetic Retinopathy ( PDR ) Compared Vitrectomy Alone</brief_title>
	<detailed_description>This randomize , double blind , control , two-center study assess feasibility , efficacy safety intravitreal ranibizumab injection apply preoperative adjunct treatment vitrectomy surgery severe proliferative diabetic retinopathy ( PDR ) . Comparator arm consist patient receive standard vitrectomy alone sham intravitreal injection preoperatively .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>male female 18 older sign informed consent Type I II diabetes mellitus severe proliferative retinopathy tractional retinal detachment , tractionalrhegmatogenous retinal detachment , tractional detachment complicate vitreous haemorrhage active severe proliferative retinopathy respond previous panretinal laser photocoagulation study eye BCVA must least light perception must exceed 70 letter use ETDRS test distance 4 meter study eye vision decrease must result severe PDR Active ocular inflammation infection History uveitis Uncontrolled glaucoma High myopia Any concurrent intraocular condition study eye opinion investigator could confound study result Former treatment antiangiogenic drug within 30 day precede Day 1 study eye History vitrectomy within 60 day precede Day 1 study eye History intraocular surgery within 30 day precede Day 1 study eye Untreated diabetes mellitus Severe hypertension ( systolic pressure high 160mmHg ) Current use systemic medication know toxic retina History thromboembolic event ( incl MI stroke ) within 5 year Major surgery within previous 3 month plan within next 28 day Known coagulation abnormality current use anticoagulative medication aspirin Known hypersensitivity ranibizumab component Women childbearing potential unless 2 method birth control apply Pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Severe proliferative diabetic retinopathy</keyword>
</DOC>